Induction of T regulatory cells by the superagonistic anti‐CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA‐transgenic mouse model of pemphigus vulgaris
Induction of T regulatory cells by the superagonistic anti‐CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA‐transgenic mouse model of pemphigus vulgaris
复制标题
DOI:
10.1111/exd.12919
复制
发表时间:
2016-04
影响因子:
3.6
通讯作者:
T. Schmidt;S. Willenborg;T. Hünig;C. Deeg;G. Sønderstrup;M. Hertl;R. Eming
中科院分区:
文献类型:
--
作者:
T. Schmidt;S. Willenborg;T. Hünig;C. Deeg;G. Sønderstrup;M. Hertl;R. Eming
Pemphigus vulgaris (PV) is a potentially life‐threatening autoimmune disease of the skin and mucous membranes. Its pathogenesis is based on IgG autoantibodies that target the desmosomal cadherins, desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1) and induce intra‐epidermal loss of adhesion. Although the PV pathogenesis is well‐understood, therapeutic options are still limited to immunosuppressive drugs, particularly corticosteroids, which are associated with significant side effects. Dsg3‐reactive T regulatory cells (Treg) have been previously identified in PV and healthy carriers of PV‐associated HLA class II alleles. Ex vivo, Dsg3‐specific Treg cells down‐regulated the activation of pathogenic Dsg3‐specific T‐helper (Th) 2 cells. In this study, in a HLA‐DRB1*04:02 transgenic mouse model of PV, peripheral Treg cells were modulated by the use of Treg‐depleting or expanding monoclonal antibodies, respectively. Our findings show that, in vivo, although not statistically significant, Treg cells exert a clear down‐regulatory effect on the Dsg3‐driven T‐cell response and, accordingly, the formation of Dsg3‐specific IgG antibodies. These observations confirm the powerful immune regulatory functions of Treg cells and identify Treg cells as potential therapeutic modulators in PV.